Search

Displaying results 1481 - 1490 of 7540 in total
  1. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [A7708]. … Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks

    Synonyms: N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
  2. Drug

    Zapomeran

    go.drugbank.com/drugs/DB21761
    Approved

    Self-amplification allows for the use of lower doses while providing higher immunogenicity compared to a conventional mRNA COVID-19 vaccine. … [L52580,L52390] The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase enzyme, which creates more copies of the mRNA itself once inside the cell.

  3. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4. … [L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized

    Synonyms: 1,4-BUTANEDIAMINE, N-(1H-BENZIMIDAZOL-2-YLMETHYL)-N-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-, 1,4-BUTANEDIAMINE, N1-(1H-BENZIMIDAZOL-2-YLMETHYL)-N1-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-
  4. Drug

    Methysergide

    go.drugbank.com/drugs/DB00247
    ApprovedWithdrawn

    It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. … Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.

    Synonyms: (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide, N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide
  5. Drug

    Acetrizoic acid

    go.drugbank.com/drugs/DB09347
    ApprovedWithdrawn

    [A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978.

  6. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. … unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain.

  7. Drug

    Cinoxacin

    go.drugbank.com/drugs/DB00827
    ApprovedWithdrawn

    Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.

  8. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis. … [L48186] Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of cytokines and growth factors.

    Synonyms: N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDE
  9. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    Phenylketonuria is a rare autosomal recessive disorder that is characterized by deficiency of the enzyme phenylalanine hydroxylase (PAH) [A33284] and affects about 1 in 10,000 to 15,000 people in the United … The primary goal of lifelong treatment of PKU, as recommended by the American College of Medical Genetics and Genomics (ACMG) guidelines, is to maintain blood Phe concentration in the range of 120 µmol

  10. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    [A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity … [A225751, A225756, A225766, A191829, L27986] Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.[L27986]